Results 271 to 280 of about 35,054 (306)

Rapid detection of Enterobacterales that produce carbapenemases

Diagnostic Microbiology and Infectious Disease, 2020
The rapid detection of carbapenemases among Enterobacterales in clinical laboratories is critical for management of patients, and infection prevention and control efforts.A study was designed to evaluate the performances of the RAPIDEC CARBA NP®, β-CARBA®, NG-Test CARBA 5®, modified carbapenem-inactivation method, and EDTA version (eCIM) assays against
Wilson W, Chan, Lorraine, Campbell, Diana, Doyle, Johann Dd, Pitout   +3 more
openaire   +2 more sources

Rapid ResaCeftazidime-Avibactam Enterobacterales NP Test: Rapid Detection of Ceftazidime-Avibactam Susceptibility in Enterobacterales

Journal of Clinical Microbiology, 2022
Ceftazidime-avibactam (CZA), a novel β-lactam/β-lactamase inhibitor combination, has good antibacterial activity against carbapenem-resistant Enterobacterales (CRE) producing class A and C and some class D carbapenemases, but in recent years, the emergence of CZA-resistant Enterobacterales ...
Luozhu Feng, Yining Zhao, Zhuocheng Yao, Xiaodong Zhang, Shufang Zheng, Lijiang Chen, Ying Zhang, Lingbo Wang, Tieli Zhou, Jianming Cao   +9 more
openaire   +2 more sources

Rapidly spreading Enterobacterales with OXA-48-like carbapenemases

Journal of Clinical Microbiology
Enterobacterales (mostly Klebsiella pneumoniae, Escherichia coli) with OXA-48-like carbapenemases (e.g., OXA-48, -181, -232, -244) are undermining the global efficiency of carbapenem therapy. In the Middle East, North Africa, and some European countries,
G. Peirano, J. Pitout
semanticscholar   +1 more source

Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019–2023)

Journal of Antimicrobial Chemotherapy
Objectives To evaluate the in vitro activity of aztreonam/avibactam against Enterobacterales from European medical centres during the 5-year period prior to its approval for clinical use in Europe.
H. Sader, J. Kimbrough, Marisa L. Winkler, M. Castanheira, R. Mendes   +4 more
semanticscholar   +1 more source

Comparing mortality in patients with carbapenemase-producing carbapenem resistant Enterobacterales and non-carbapenemase-producing carbapenem resistant Enterobacterales bacteremia

Diagnostic Microbiology and Infectious Disease, 2021
Carbapenem-resistant Enterobacterales (CRE) are classified as either carbapenemase-producing CRE (CP-CRE) or non-carbapenemase-producing CRE (non-CP-CRE) based on their mechanism of carbapenem resistance. Few studies have compared outcomes associated with each type of infection.
Michael R, Hovan, Navaneeth, Narayanan, Vanessa, Cedarbaum, Tanaya, Bhowmick, Thomas J, Kirn   +4 more
openaire   +2 more sources

Carbapenem-resistant Enterobacterales bloodstream infections related to death in two Brazilian tertiary hospitals

BMC Infectious Diseases
Bloodstream infection (BSI) caused by carbapenem-resistant Enterobacterales (CRE) is a major global public health concern due to its high lethality and limited treatment options.
Lorena Galvão de Araújo, Kehvyn Cedeño, A. P. Bomfim, Márcio de Oliveira Silva, Ana Verena Mendes, M. Barberino, E. Gouveia, Fabianna Márcia M. Bahia, M. D. dos Reis, Joice Neves Reis   +9 more
semanticscholar   +1 more source

Clinical outcomes in patients infected with ertapenem-only-resistant Enterobacterales versus multi-carbapenem-resistant Enterobacterales

Journal of Antimicrobial Chemotherapy
Abstract Background Use of anti-carbapenem-resistant Enterobacterales (anti-CRE) agents such as ceftazidime/avibactam has been associated with improved clinical outcome in cohorts that primarily include patients infected with CRE that are resistant to meropenem (MCRE).
Gregory Weston, Abhigya Giri, Lauren Komarow, Lizhao Ge, Keri R Baum, Erin Abbenante, Jason C Gallagher, Jesse T Jacob, Keith S Kaye, Angela C Kim, W Charles Huskins, Marcus Zervos, Erica Herc, Robin Patel, David Van Duin, Yohei Doi   +15 more
openaire   +2 more sources

Clinical features and outcomes of infections caused by metallo-β-lactamases producing Enterobacterales: a 3-year prospective study from an endemic area.

Clinical Infectious Diseases, 2023
BACKGROUND Metallo-β-lactamases (MBL)-producing Enterobacterales are increasing worldwide. Our aim was to describe clinical features, treatments and outcomes of infections by MBL-Enterobacterales.
M. Falcone, Cesira Giordano, A. Leonildi, V. Galfo, Aurelio Lepore, L. Suardi, N. Riccardi, Simona Barnini, G. Tiseo   +8 more
semanticscholar   +1 more source

Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed Metallo-β-lactamase production: a systematic review and meta-analysis

Expert Review of Anti-Infective Therapy
Introduction Carbapenem-resistant Enterobacterales (CRE) due to Metallo-β-lactamase (MBL) production are treated with either polymyxins or the novel combination of ceftazidime-avibactam and aztreonam (AA). This study aims to evaluate the 30-day mortality
Nitin Gupta, Carl Boodman, P. Prayag, A. Manesh, T. P. Kumar   +4 more
semanticscholar   +1 more source

Adverse Environmental Perturbations May Threaten Kelp Farming Sustainability by Exacerbating Enterobacterales Diseases.

Environmental Science and Technology
Globally kelp farming is gaining attention to mitigate land-use pressures and achieve carbon neutrality. However, the influence of environmental perturbations on kelp farming remains largely unknown.
Yongyu Zhang, Shailesh Nair, Zenghu Zhang, Jiulong Zhao, Hanshuang Zhao, Longfei Lu, Lirong Chang, Nianzhi Jiao   +7 more
semanticscholar   +1 more source